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mice exhibited exaggerated induction of matrix metalloproteinase (MMP)-9 but similar induction of MMP-2. HO-2 deficiency also led to lower AVF blood flow when AVFs were created in uremia, the latter induced by subtotal nephrectomy. We conclude that HO-2 critically contributes to the adequacy of AVF blood flow and function. arteriovenous fistula; heme oxygenase-2; hemodialysis; vascular access HEME OXYGENASE (HO) represents the major mechanism whereby heme is degraded, and such activity exists in two isoforms, the inducible, HO-1, and the constitutive, HO-2. In addition to degrading heme, either HO isoform generates carbon monoxide, bile pigments, and iron, the latter sequestered by ferritin or exported extracellularly by ferrportin (1, 31) . Carbon monoxide, among its other properties, is recognized as a vasorelaxant molecule as well as an anti-inflammatory one, and bile pigments can exert antioxidant and antiinflammatory effects. Through these and other actions, HO-1 has been shown to be a protectant in diverse models of tissue injury. Interest also exists regarding the protective effects of HO-2 in tissue injury, but thus far this area has received substantially less attention compared with the study of HO-1 (1, 31) .
We previously demonstrated that induction of HO-1 is a beneficial response following the creation of an arteriovenous fistula (AVF) (20) , a study motivated by the recognition of the pressing problem of hemodialysis vascular access dysfunction and the need for new therapeutic strategies for such dysfunction (2, 16, 22, 26, 27, 40, 41, 45) . As emphasized by the Fistula First Initiative, the AVF is the preferred hemodialysis vascular access because such accesses, compared with arteriovenous grafts and central venous hemodialysis catheters, exhibit greater duration in function, are attended by less morbidity and mortality, and incur lower costs (2, 16, 22, 26, 27, 40, 41, 45) . However, the outcomes for AVFs created for use as hemodialysis vascular accesses are decidedly grim: 1) ϳ50% of all such accesses never become sufficiently functional such that they can ever be used as hemodialysis vascular accesses; 2) mature and usable AVFs often require repeated interventions to maintain functionality; and 3) the overall longevity of a functional AVF is relatively limited, commonly necessitating the placement of subsequent vascular accesses during the lifetime of the hemodialysis patient. Understanding the mechanisms whereby AVFs either fail to mature or decline in function is thus a critical issue in the care of patients with chronic kidney disease (CKD).
The present study was undertaken to determine whether HO-2 contributes to the functionality of an AVF, hypothesizing that a constitutive isoform of HO, already in place in the vasculature at the time of AVF creation (and distinct from HO-1, which requires induction), would be conducive to the ensuing and expected augmentation of blood flow once an AVF is created. Because AVF function is defined by blood flow through the AVF, this quantitative index comprised our principal approach in assessing AVF function.
Our evaluation of the role of HO-2 involved a multilayered approach that included the following studies: examination of vascular expression of HO-2; the creation of AVFs in HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice; the in vitro assessment of vasorelaxant responses of the same artery (carotid) used in the AVF in HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice; the in vivo assessment of acute increments in carotid blood flow in response to acetylcholine in HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice; and examination of the role of HO-2 in augmenting AVF blood flow in uremia, the latter induced by subtotal nephrectomy before the creation of the AVF.
MATERIAL AND METHODS
Murine AVF model. All studies were approved by the Institutional Animal Care and Use Committee of Mayo Clinic and performed according to the guidelines of the National Institutes of Health. In these studies, a murine AVF model created by an end-to-side anastomosis between the right carotid artery and jugular vein was employed, as we described previously (19, 20, 21) . In initial studies, male C57Bl6J mice (Jackson Laboratory, Bar Harbor, ME) ranging from 9 -12 wk of age were employed to characterize HO-2 expression in the arterial limb of the murine AVF. To determine the functional significance of HO-2 in the AVF, we utilized HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice, which we have employed in prior studies (13, 32) . Colonies of these mice having targeted disruption of the HO-2 gene, as described by Poss and Tonegawa (37) , were maintained by mating of HO-2 ϩ/Ϫ males and females and were genotyped at the time of weaning using a PCR method. Mice were age matched (in the range of 18 -35 wk) and sex matched for these studies. AVFs were created in HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice, and the nonoperated, contralateral carotid arteries were used as controls. Four weeks after the creation of the AVF, blood flow through the AVF and the contralateral carotid artery was measured using a perivascular flow meter (TS420; Transonic Systems), as we previously described (21) . In addition, assessment of gene expression was performed on the arterial limb of the AVF and the contralateral carotid artery of HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice 1 wk after the creation of the AVF.
Murine model of CKD. For studies examining the effect of HO-2 deficiency on AVF blood flow in uremia, CKD was induced in mice by subtotal nephrectomy, the latter based on a two-step renal ablation procedure as described by Gagnon and Duguid (14, 15) . Briefly, in the first step, mice were anesthetized with pentobarbital sodium (60 mg/kg ip) and, via a 2-cm flank incision, the upper third and lower third of the right kidney were ablated by electrocautery. In the second surgery, the left kidney was removed 1 wk later. Control animals received sham operations that included flank incisions and exposure of kidneys. Seven to 10 days after the second surgery, renal function was assessed by measurement of blood urea nitrogen (BUN) levels (Urea Nitrogen Assay kit; Pointe Scientific, Canton, MI). As described previously (14, 15) , this CKD model resulted in an approximate doubling of BUN levels, which did not progress over the time course of these studies. At 2 wk after the second surgery, an AVF was created as described above.
Measurement of increments in carotid artery blood flow induced by acetylcholine in vivo. Blood flow responses to acetylcholine were determined in the carotid arteries of HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice, as described previously (21) . Briefly, following baseline flow measurements, the carotid artery was bathed in a solution of acetylcholine (100 M in normal saline; Sigma, St. Louis, MO), and the solution was refreshed every 2 min for the duration of the study. Ten minutes after acetylcholine treatment commenced, blood flow was again determined.
Assessment of mRNA expression by quantitative real-time RT-PCR. Gene expression in carotid arteries was assessed by quantitative real-time RT-PCR, as previously described (19, 20, 36) . Total RNA was extracted and further purified using the TRIzol method (Invitrogen, Carlsbad, CA) and an RNeasy Mini kit (Qiagen, Valencia, CA), respectively, and cDNA was synthesized employing random hexamers (Transcriptor First-Strand cDNA Synthesis kit; Roche Applied Science, Indianapolis, IN). The probe and primers used for these assessments were obtained as assay sets (TaqMan Gene Expression Assays; Applied Biosystems, Foster City, CA) and employed with the following parameters: 10 min at 95°C, followed by 40 cycles of amplification for 15 s at 95°C and 1 min at 60°C. Expression of 18S rRNA was similarly determined and used for normalization of target mRNA expression.
Assessment of vascular reactivity in carotid arteries. Vascular reactivity was examined in mouse carotid arteries as described in our prior studies (11, 12) . Briefly, carotid arteries were carefully removed and placed immediately into cold (4°C) modified Krebs-Ringer bicarbonate solution containing (in mM) 118.6 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25.1 NaHCO3, 0.026 EDTA, and 10.1 glucose. After careful dissection to remove connective tissue, segments (4 mm long) of carotid arteries were transferred to small vessel chambers (Living Systems Instrumentation, St. Albans, VT) filled with Krebs-Ringer bicarbonate solution with continuous aeration (94% O 2 and 6% CO2 gas) at 37°C. Proximal and distal ends of the vessels were mounted and sutured onto two small glass microcannulas (positioned in the vessel chamber). The transluminal pressure of 50 mmHg was set at a level that was found to be optimal for contractions to U-46619 (3 ϫ 10 Ϫ8 M). Endothelium-dependent relaxations to acetylcholine (10 Ϫ9 to 10 Ϫ5 M) were first obtained after stabilization of submaximal contraction to the thromboxane analog U-46619 (3 ϫ 10 Ϫ8 to 10
Ϫ9 to 10 Ϫ5 M) were obtained in carotid arteries after submaximal contraction to U-46619 (3 ϫ 10 Ϫ8 to 10 Ϫ7 M). Relaxation responses were then calculated as a percentage of maximal relaxation induced by 3 ϫ 10 Ϫ4 M papaverine.
Immunohistochemical localization of HO-2 expression.
Immunohistochemical analysis of HO-2 expression was performed, as described previously, on 5-m sections prepared from formalin-fixed, paraffin-embedded arterial limbs of the AVF and in contralateral control carotid arteries. A rabbit polyclonal antibody (catalog no. ADI-SPA-897) was used as the primary antibody (20, 44) .
Histological evaluation of the AVF. A semiquantitative analysis of luminal narrowing in the juxta-anastomotic regions of the AVF in HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice was performed (44) . Hematoxylin-and eosin-stained sections were assessed for the degree of neointimal hyperplasia, mural thrombus formation, and vessel wall thickening, and the percentage of AVFs exhibiting luminal narrowing Ͼ50% and 75% were determined.
Statistical analysis. Results are means Ϯ SE and considered statistically significant for P Ͻ 0.05. The Student's t-test was used for parametric data, and the Mann-Whitney U-test was employed for nonparametric data. AVF failure was assessed using Fisher's exact test.
RESULTS
Immunohistochemical studies of the intact carotid artery demonstrated that HO-2 was expressed in the endothelium and smooth muscle cell layer under basal conditions and that such cellular expression appeared more prominent in the AVF in wild-type C57Bl6 mice 2 wk after AVF creation (Fig. 1) . At earlier time points, HO-2 mRNA expression in the AVF was unchanged at 3 days and modestly increased at 7 days following the creation of the AVF (Fig. 2) . This mRNA temporal profile for HO-2 significantly contrasted with that displayed by HO-1 mRNA; in the same arterial segments of the AVF at these same time points, HO-1 mRNA was markedly induced (10-and 7-fold, respectively) in the AVF (Fig. 3) .
To determine the functional significance of HO-2 in the AVF, the AVF was created in HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice. HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice derived from a colony originally generated by Poss and Tonegawa (37) and maintained by our laboratories (13, 32) have comparable growth, body weights, and systolic blood pressure. For example, in cohorts of HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice with matched numbers of male and female mice and of comparable age (29 Ϯ 1 and 28 Ϯ 1 wk), the body weights (31 Ϯ 2 and 30 Ϯ 1 g) and systolic blood pressures (114 Ϯ 3 and 110 Ϯ 4 mmHg) were not significantly different.
Creation of the AVF, as expected, led to increased carotid blood flow in the AVF compared with that in the contralateral intact carotid artery in HO-2 ϩ/ϩ mice and as measured at 4 wk after the creation of the AVF (Fig. 4) . Remarkably, this increase in AVF blood flow was completely absent in the setting of HO-2 deficiency in these studies undertaken at 4 wk (Fig. 4) . Moreover, AVF failure, defined as the lack of discernible and measurable blood flow through the AVF, was markedly increased in the setting of HO-2 deficiency (Fig. 5) .
Histological analyses were undertaken at the juxta-anastomotic region in the AVF for luminal narrowing as a consequence of neointimal hyperplasia, mural thrombus, and vessel wall thickening. Although there was an approximately twofold or greater increase in the percentages of AVFs in HO-2 Our prior studies demonstrated that the exacerbatory effect of HO-1 deficiency in the AVF arose, in part, from exaggerated induction of matrix metalloproteinase (MMP)-9, a mitogenic, vasculopathic molecule (20) . We thus examined expression of MMP-9 in the AVF. As shown in HO-2 Ϫ/Ϫ mice was comparable (Fig. 7) ; thus neither the deterioration in AVF function nor the increased AVF expression of MMP-9, incurred by HO-2 deficiency, could be ascribed to blunted induction of HO-1. Furthermore, this increased induction of MMP-9 mRNA in the AVF in HO-2-deficient mice was not accompanied by increased expression of MMP-2 mRNA (Fig. 8) , as was indeed the case in prior studies of the AVF in HO-1 Ϫ/Ϫ mice. We next questioned whether intrinsic abnormalities in vasorelaxation exist in the carotid artery in the setting of HO-2 deficiency, since such functional defects may contribute to impaired AVF function. We thus examined in vitro vasorelaxant responses of the carotid artery in HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice. However, neither endothelium-dependent nor endotheliumindependent vasorelaxant responses were different in HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice (Figs. 9 and 10, respectively). These findings are consistent with measurements of acetylcholine-induced increments in carotid artery blood flow in vivo that were comparable in HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice (0.14 Ϯ 0.02 and 0.11 Ϯ 0.02 ml/min, n ϭ 6 in each group, P ϭ not significant).
AVFs are created in an uremic environment. We thus questioned whether AVF blood flow in the uremic milieu is impaired by concomitant deficiency of HO-2. Two weeks after subtotal nephrectomy was performed in HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice, an AVF was created by anastomosing the right carotid artery and the right jugular vein. Two weeks after the mice subjected to the uremia followed by the AVF. AVF blood flow in these groups is shown in Fig. 11 ; as demonstrated, AVF blood flow, measured 2 wk after AVF creation in uremic mice, was reduced in the setting of HO-2 deficiency; deficiency of HO-2 did not significantly reduce blood flow in the intact, contralateral artery in the uremic milieu. It should be noted that these AVF blood flow studies were performed 2 wk after AVF creation, whereas studies summarized in Fig. 4 were performed after 4 wk; in this AVF model, decrease in blood flow and AVF closure start at ϳ3 wk.
DISCUSSION
The present studies demonstrate that the genetic absence of HO-2 substantially impairs the function of the murine AVF, and taken together with prior studies that specifically addressed the role of HO-1 in the AVF (20) , they support the contribution of both the constitutive and inducible isoforms of HO in enabling functional adaptation following the creation of an AVF; additionally, these studies demonstrate that loss of either HO isoform is not redressed by the presence of the other in preserving the functionality of an AVF.
HO-2 protein is prominently expressed in the intact murine vasculature, and somewhat more so in the AVF, as shown in immunohistochemical analysis undertaken at 2 wk. In the preceding time frame, HO-2 mRNA expression in the AVF ϩ/ϩ and HO-2 Ϫ/Ϫ mice that were subjected to subtotal nephrectomy 2 wk before AVF creation (CKD) (n ϭ 8 in each group). Measurements of AVF blood flow were undertaken at 2 wk after AVF creation. Values are means Ϯ SE. *P Ͻ 0.05 vs. HO-2 ϩ/ϩ AVF with CKD. was unchanged at 3 days and modestly induced at 1 wk, thus differing sharply from the robust induction observed for HO-1 mRNA in the AVF in the same vascular segments and at the same time points. Certain distinct features of HO-2 and HO-1 merit consideration as regards their relative functional effects in the vasculature. First, because HO-2, unlike HO-1, is constitutively expressed and already in place in the vasculature, the vasorelaxant actions of HO-2 are tonically exerted at the time of AVF creation and not recruited thereafter (and thus delayed) as is the case for HO-1, which necessitates an obligatory period of induction. Second, HO activity from HO-2 is controlled and measured and not the robust, even fulminant, activity engendered by induction of HO-1; such marked induction of HO-1 and attendant HO activity may generate products of HO activity in such quantities that vasoprotective effects may not necessarily ensue. Third, the biological effects of the HO system may depend on not just HO activity but also signaling by the specific HO-1 and HO-2 proteins (23, 24, 28) ; notably, HO-1 and HO-2 represent distinct genes that generate specific proteins (1, 31) . Fourth, an analogy with the isoforms of nitric oxide synthase (NOS) may be considered: although constitutive endothelial (eNOS) and inducible NOS (iNOS) have the same enzymic activities, their functional significance in physiological and pathophysiological states may substantially differ, and the behavior of one isoform cannot be used to predict the behavior of the other. The present studies demonstrate the importance of constitutive HO-2 expression in the adaptive responses that underlie enhanced blood flow following the creation of an AVF.
To determine whether deficiency of HO-2 was attended by an intrinsic abnormality in vascular behavior, we directly examined the vascular reactivity of the carotid artery. To our surprise, the absence of HO-2 in the carotid artery impaired neither endothelium-dependent nor endothelium-independent vasorelaxation of the carotid artery. Such similarity in carotid vascular reactivity in vitro in HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice was accompanied by similar increments in acetylcholine-induced carotid blood flow in vivo and comparable blood flow in the intact carotid artery (contralateral to the AVF) in HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice. Thus preexisting abnormalities either in vasorelaxant responses or in carotid blood flow cannot be implicated as contributory mechanisms in the failure of blood flow to increase when an AVF is created in the setting of HO-2 deficiency. However, unlike this seeming lack of a functional effect of deficiency of HO-2 in the intact, "unstressed" vasculature, such deficiency of HO-2 significantly impairs vascular behavior when the vasculature is subjected to hemodynamic stress as imposed by the creation of an AVF. Furthermore, HO-2 was also required in augmenting AVF blood flow when such hemodynamic stress was imposed in the presence of CKD, the latter representing the setting in which the AVF is created for use as a hemodialysis vascular access.
Our prior studies demonstrated that deficiency of HO-1 impairs the functionality of the AVF, an effect likely reflecting, in part, exaggerated expression of MMP-9. Substantial evidence indicates that MMP-9 exerts vasculopathic effects that include the marked stimulation of proliferation and migration of smooth muscle cells and proinflammatory effects (6, 9, 46) ; upregulation of MMP-9 is implicated in the promotion of neotimal hyperplasia in the injured vasculature and assorted vasculopathies that include dysfunction of hemodialysis vascular accesses (6, 7, 8, 9, 10, 20, 25, 29, 33, 46) . We thus examined expression of MMP-9 and HO-1 in the AVF in HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice. We observed that the induction of MMP-9 in the AVF was exaggerated in the setting of HO-2 deficiency, whereas HO-1 was comparably induced in the AVF in HO-2 ϩ/ϩ and HO-2 Ϫ/Ϫ mice. This indicates that HO-2, as distinct from HO-1, may exert a suppressive effect on MMP-9 in the AVF. Also of note is that the observed augmented expression of MMP-9 in the AVF, induced by the deficiency of HO-2, was not accompanied by augmented induction of MMP-2, as was the case in prior studies in the AVF when MMP-9 expression was exaggerated by HO-1 deficiency. Interestingly, levels of MMP-9 are increased in uremia (35) , and it is thus tempting to speculate that the impairment in AVF blood flow induced by HO-2 deficiency when the AVF is created in the uremic milieu may reflect further augmentation in MMP-9 levels.
Other cellular effects of HO-2, in addition to those involving suppression of MMP-9, may be relevant to the observed findings. HO-2, for example, is a survival factor in the endothelium as shown by the observations that HO-2 deficiency exacerbates apoptosis of endothelial cells incurred by either glutamate or TNF-␣ (3, 34), whereas increased amounts of HO-2 protein reduce the lethal effects of hypoxia in endothelial cells (18) . Deficiency of HO-2 promotes the appearance of an activated phenotype in aortic endothelial cells (4), and following the wounding of the corneal epithelium, deficiency of HO-2 enhances inflammatory responses and impairs reparative responses (5, 17) . Exacerbation of inflammatory responses induced by the deficiency of HO-2 may thus contribute to the decreased AVF flow and increased AVF failure observed in HO-2-deficient mice.
A relative merit of an approach based on HO-2 Ϫ/Ϫ mice, compared with the use of chemical inhibitors of HO activity, is that such mutant mice enable the assessment of the specific involvement of the HO-2 isoform in pathophysiological states; however, relatively few studies to date have employed this approach in examining the role of HO-2 in vasorelaxant responses. Based on analyses in HO-2 Ϫ/Ϫ mice, the conclusion has been reached that HO-2 contributes, in part, to acetylcholine-induced dilation of pial arterioles (38) , whereas other studies have demonstrated that CO emanating from HO-2 may be vasoconstrictive in pial arterioles and that hypoxia induces cerebral vasodilation by suppressing generation of CO by HO-2 (30). Neither hypoxia-induced pulmonary hypertension nor reduction in renal blood flow incurred by angiotensin II or nitro-L-arginine methyl ester (L-NAME) is altered by the genetic deficiency of HO-2 (39, 43) . A mild increase in blood pressure (not observed in the present studies or in prior studies) has been described in HO-2 Ϫ/Ϫ mice, along with an impaired vasorelaxant response in aortic rings (42) . The present studies demonstrate that chronic augmentation in blood flow as occurs in an AVF is fundamentally dependent on HO-2, but they do not reveal an intrinsic impairment in acute vasorelaxation of the carotid artery either in vitro or in vivo. It would be of interest whether other states attended by chronic augmentation in systemic or regional blood flow require HO-2 for such a response, including states characterized by increased renal blood flow such as diabetes mellitus, following uninephrectomy, high dietary protein intake, and pregnancy.
In summary, to the best of our knowledge, the present studies are the first to examine and demonstrate the functional significance of vascular expression of the constitutive HO isoform HO-2 in the AVF: although without a discernible functional effect in the unstressed vasculature, HO-2 is required for maintaining augmented blood flow in the vasculature subjected to the chronic hemodynamic stress imposed by an AVF, either in the setting of intact renal function or in the uremic milieu. On the basis of our findings, we speculate that variability in constitutive expression of HO-2 may be considered as a possible contributor to the unacceptably high failure rates for maturation of AVFs when employed as hemodialysis vascular accesses and that HO-2 may be the target of novel therapeutic approaches seeking to promote the maturation and longevity of hemodialysis AVFs.
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